Literature DB >> 31003750

Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: A systematic review and meta-analysis.

Xingran Du1, Xinfeng Xu2, Jing Yao3, Kaili Deng4, Sixia Chen3, Ziyan Shen3, Lihua Yang1, Ganzhu Feng5.   

Abstract

BACKGROUND: Carbapenem-resistant Acinetobacter baumannii (CRAB) tops the list of threats to human health. Studies exploring predictors of mortality in patients with CRAB infection produced conflicting results.
METHODS: A systematic search of the PubMed, Embase, and the Cochrane Library databases was performed from inception to June 2018 to identify studies reporting mortality predictors in patients infected with CRAB. Two authors independently assessed trials for inclusion and data extraction.
RESULTS: A total of 19 observational studies were enrolled in this study. Factors associated with mortality of patients infected with CRAB were inappropriate empirical antimicrobial treatment (odds ratio [OR], 5.04; 95% confidence interval [CI], 2.56-9.94), septic shock (OR, 5.65; 95% CI, 2.35-13.57), chronic liver disease (OR, 2.36; 95% CI, 1.33-4.16), chronic renal disease (OR, 2.02; 95% CI, 1.37-2.99), hypertension (OR, 1.74; 95% CI, 1.08-2.80), neutropenia (OR, 3.31; 95% CI, 1.25-8.77), immunosuppressant use (OR, 3.15; 95% CI, 1.94-5.11), total parenteral nutrition (OR, 1.66; 95% CI, 1.08-2.56), and intubation (OR, 5.03; 95% CI, 2.33-10.87). Acute Physiology and Chronic Health Evaluation II score at admission and Pitt bacteremia score at the onset of CRAB bacteremia were higher in nonsurvivors.
CONCLUSIONS: Our study suggests that severity of baseline condition and receiving inappropriate experience antibiotic therapy are major risk factors for higher mortality in patients with CRAB infections. These findings may help clinicians to take appropriate preventive measures and decrease mortality in such patients.
Copyright © 2019 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bloodstream infection; Carbapenem resistance; Nosocomial pneumonia; Risk factors

Mesh:

Substances:

Year:  2019        PMID: 31003750     DOI: 10.1016/j.ajic.2019.03.003

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  31 in total

1.  Risk factors and clinical outcomes for intensive care unit patients with mul-tidrug-resistant Acinetobacter spp. bacteremia.

Authors:  Malbaša Đekić; T Dugandžija; G Dragovac; D Medić; M Paut Kusturica
Journal:  Hippokratia       Date:  2020 Jan-Mar       Impact factor: 0.471

2.  Treatment, Clinical Outcomes, and Predictors of Mortality among a National Cohort of Admitted Patients with Acinetobacter baumannii Infection.

Authors:  Haley J Appaneal; Vrishali V Lopes; Kerry L LaPlante; Aisling R Caffrey
Journal:  Antimicrob Agents Chemother       Date:  2022-01-10       Impact factor: 5.938

Review 3.  Systematic review and meta-analysis of the proportion and associated mortality of polymicrobial (vs monomicrobial) pulmonary and bloodstream infections by Acinetobacter baumannii complex.

Authors:  Stamatis Karakonstantis; Evangelos I Kritsotakis
Journal:  Infection       Date:  2021-07-14       Impact factor: 3.553

4.  The role of combination therapy in the treatment of severe infections caused by carbapenem resistant gram-negatives: a systematic review of clinical studies.

Authors:  Alessia Savoldi; Elena Carrara; Laura J V Piddock; Francois Franceschi; Sally Ellis; Margherita Chiamenti; Damiano Bragantini; Elda Righi; Evelina Tacconelli
Journal:  BMC Infect Dis       Date:  2021-06-09       Impact factor: 3.090

5.  Time series analysis of antibacterial usage and bacterial resistance in China: observations from a tertiary hospital from 2014 to 2018.

Authors:  Shuangshuang Zeng; Zhijie Xu; Xiang Wang; Wanli Liu; Long Qian; Xi Chen; Jie Wei; Minwen Zhu; Zhicheng Gong; Yuanliang Yan
Journal:  Infect Drug Resist       Date:  2019-08-28       Impact factor: 4.003

6.  Remdesivir, Renal Function and Short-Term Clinical Outcomes in Elderly COVID-19 Pneumonia Patients: A Single-Centre Study.

Authors:  Edoardo Biancalana; Martina Chiriacò; Paolo Sciarrone; Alessandro Mengozzi; Sandra Mechelli; Stefano Taddei; Anna Solini
Journal:  Clin Interv Aging       Date:  2021-06-03       Impact factor: 4.458

7.  Cefiderocol-Based Combination Therapy for "Difficult-to-Treat" Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives.

Authors:  Davide Fiore Bavaro; Alessandra Belati; Lucia Diella; Monica Stufano; Federica Romanelli; Luca Scalone; Stefania Stolfa; Luigi Ronga; Leonarda Maurmo; Maria Dell'Aera; Adriana Mosca; Lidia Dalfino; Salvatore Grasso; Annalisa Saracino
Journal:  Antibiotics (Basel)       Date:  2021-05-29

8.  Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects.

Authors:  Jason D Lickliter; Kenneth Lawrence; John O'Donnell; Robin Isaacs
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

9.  Genetic Diversity of Imipenem-Resistant Acinetobacter baumannii Infections at an Intensive Care Unit.

Authors:  Amani Alnimr; Aisha Alamri; Afnan Alsultan
Journal:  Crit Care Res Pract       Date:  2020-02-21

10.  Characterization of Acinetobacter baumannii Copper Resistance Reveals a Role in Virulence.

Authors:  Caitlin L Williams; Heather M Neu; Yonas A Alamneh; Ryan M Reddinger; Anna C Jacobs; Shweta Singh; Rania Abu-Taleb; Sarah L J Michel; Daniel V Zurawski; D Scott Merrell
Journal:  Front Microbiol       Date:  2020-02-06       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.